Trial · NCT00690443
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change in LDL-C After 8 Weeks of Therapy | Atorvastatin 20 mg | -39.6 | Standard Deviation 14.35 | Percent Change | |
| Percent Change in LDL-C After 8 Weeks of Therapy | Atorvastatin 20 mg + Lomitapide | -49.9 | Standard Deviation 26.78 | Percent Change | |
| Percent Changes in LDL-C at Week 4 + Baseline Serum Lipoproteins (TC, Non-HDL, VLDL, TGs, HDL-C, Apolopoproteins A1 and B), High Sensitivity C-reactive Protein and Change in Body Weight. | Atorvastatin 20 mg | Change in LDL-C | -42.5 | Standard Deviation 12.70 | Percent |
| Percent Changes in LDL-C at Week 4 + Baseline Serum Lipoproteins (TC, Non-HDL, VLDL, TGs, HDL-C, Apolopoproteins A1 and B), High Sensitivity C-reactive Protein and Change in Body Weight. | Atorvastatin 20 mg + Lomitapide | Change in LDL-C | -51.0 | Standard Deviation 18.34 | Percent |
| Percent Changes in LDL-C at Week 4 + Baseline Serum Lipoproteins (TC, Non-HDL, VLDL, TGs, HDL-C, Apolopoproteins A1 and B), High Sensitivity C-reactive Protein and Change in Body Weight. | Atorvastatin 20 mg | Change in TC | -31.3 | Standard Deviation 9.23 | Percent |
| Percent Changes in LDL-C at Week 4 + Baseline Serum Lipoproteins (TC, Non-HDL, VLDL, TGs, HDL-C, Apolopoproteins A1 and B), High Sensitivity C-reactive Protein and Change in Body Weight. | Atorvastatin 20 mg + Lomitapide | Change in TC | -38.1 | Standard Deviation 15.38 | Percent |
| Percent Changes in LDL-C at Week 4 + Baseline Serum Lipoproteins (TC, Non-HDL, VLDL, TGs, HDL-C, Apolopoproteins A1 and B), High Sensitivity C-reactive Protein and Change in Body Weight. | Atorvastatin 20 mg | Change in TGs | -21.5 | Standard Deviation 18.31 | Percent |
| Percent Changes in LDL-C at Week 4 + Baseline Serum Lipoproteins (TC, Non-HDL, VLDL, TGs, HDL-C, Apolopoproteins A1 and B), High Sensitivity C-reactive Protein and Change in Body Weight. | Atorvastatin 20 mg + Lomitapide | Change in TGs | -17.8 | Standard Deviation 28.32 | Percent |
| Percent Changes in LDL-C at Week 4 + Baseline Serum Lipoproteins (TC, Non-HDL, VLDL, TGs, HDL-C, Apolopoproteins A1 and B), High Sensitivity C-reactive Protein and Change in Body Weight. | Atorvastatin 20 mg | Change in HDL-C | 6.7 | Standard Deviation 8.07 | Percent |
| Percent Changes in LDL-C at Week 4 + Baseline Serum Lipoproteins (TC, Non-HDL, VLDL, TGs, HDL-C, Apolopoproteins A1 and B), High Sensitivity C-reactive Protein and Change in Body Weight. | Atorvastatin 20 mg + Lomitapide | Change in HDL-C | -1.9 | Standard Deviation 10.73 | Percent |
| Percent Changes in LDL-C at Week 4 + Baseline Serum Lipoproteins (TC, Non-HDL, VLDL, TGs, HDL-C, Apolopoproteins A1 and B), High Sensitivity C-reactive Protein and Change in Body Weight. | Atorvastatin 20 mg | Change in non-HDL-C | -39.6 | Standard Deviation 10.78 | Percent |
| Percent Changes in LDL-C at Week 4 + Baseline Serum Lipoproteins (TC, Non-HDL, VLDL, TGs, HDL-C, Apolopoproteins A1 and B), High Sensitivity C-reactive Protein and Change in Body Weight. | Atorvastatin 20 mg + Lomitapide | Change in non-HDL-C | -45.8 | Standard Deviation 17.68 | Percent |
| Percent Changes in LDL-C at Week 4 + Baseline Serum Lipoproteins (TC, Non-HDL, VLDL, TGs, HDL-C, Apolopoproteins A1 and B), High Sensitivity C-reactive Protein and Change in Body Weight. | Atorvastatin 20 mg | Change in Apo B | -33.6 | Standard Deviation 10.19 | Percent |
| Percent Changes in LDL-C at Week 4 + Baseline Serum Lipoproteins (TC, Non-HDL, VLDL, TGs, HDL-C, Apolopoproteins A1 and B), High Sensitivity C-reactive Protein and Change in Body Weight. | Atorvastatin 20 mg + Lomitapide | Change in Apo B | -37.7 | Standard Deviation 17.05 | Percent |
| Percent Changes in LDL-C at Week 4 + Baseline Serum Lipoproteins (TC, Non-HDL, VLDL, TGs, HDL-C, Apolopoproteins A1 and B), High Sensitivity C-reactive Protein and Change in Body Weight. | Atorvastatin 20 mg | Change in Apo A-1 | 4.8 | Standard Deviation 7.53 | Percent |
| Percent Changes in LDL-C at Week 4 + Baseline Serum Lipoproteins (TC, Non-HDL, VLDL, TGs, HDL-C, Apolopoproteins A1 and B), High Sensitivity C-reactive Protein and Change in Body Weight. | Atorvastatin 20 mg + Lomitapide | Change in Apo A-1 | -7.8 | Standard Deviation 8.85 | Percent |
| Percent Changes in LDL-C at Week 4 + Baseline Serum Lipoproteins (TC, Non-HDL, VLDL, TGs, HDL-C, Apolopoproteins A1 and B), High Sensitivity C-reactive Protein and Change in Body Weight. | Atorvastatin 20 mg | Change in hs-CRP | -12.0 | Standard Deviation 43.21 | Percent |
| Percent Changes in LDL-C at Week 4 + Baseline Serum Lipoproteins (TC, Non-HDL, VLDL, TGs, HDL-C, Apolopoproteins A1 and B), High Sensitivity C-reactive Protein and Change in Body Weight. | Atorvastatin 20 mg + Lomitapide | Change in hs-CRP | 60.5 | Standard Deviation 187.50 | Percent |
| Percent Changes in LDL-C at Week 4 + Baseline Serum Lipoproteins (TC, Non-HDL, VLDL, TGs, HDL-C, Apolopoproteins A1 and B), High Sensitivity C-reactive Protein and Change in Body Weight. | Atorvastatin 20 mg | Change in body weight | 0.0 | Standard Deviation 1.38 | Percent |
| Percent Changes in LDL-C at Week 4 + Baseline Serum Lipoproteins (TC, Non-HDL, VLDL, TGs, HDL-C, Apolopoproteins A1 and B), High Sensitivity C-reactive Protein and Change in Body Weight. | Atorvastatin 20 mg + Lomitapide | Change in body weight | -0.7 | Standard Deviation 1.49 | Percent |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00690443/results